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Abstract: Extensive microbial colonization of the infant gastrointestinal tract starts after parturition.
There are several parallel mechanisms by which early life microbiome acquisition may proceed,
including early exposure to maternal vaginal and fecal microbiota, transmission of skin associated
microbes, and ingestion of microorganisms present in breast milk. The crucial role of vertical
transmission from the maternal microbial reservoir during vaginal delivery is supported by the
shared microbial strains observed among mothers and their babies and the distinctly different
gut microbiome composition of caesarean-section born infants. The healthy infant colon is often
dominated by members of the keystone genus Bifidobacterium that have evolved complex genetic
pathways to metabolize different glycans present in human milk. In exchange for these host-derived
nutrients, bifidobacteria’s saccharolytic activity results in an anaerobic and acidic gut environment that
is protective against enteropathogenic infection. Interference with early-life microbiota acquisition
and development could result in adverse health outcomes. Compromised microbiota development,
often characterized by decreased abundance of Bifidobacterium species has been reported in infants
delivered prematurely, delivered by caesarean section, early life antibiotic exposure and in the
case of early life allergies. Various microbiome modulation strategies such as probiotic, prebiotics,
synbiotics and postbiotics have been developed that are able to generate a bifidogenic shift and
help to restore the microbiota development. This review explores the evolutionary ecology of
early-life type Bifidobacterium strains and their symbiotic relationship with humans and discusses
examples of compromised microbiota development in which stimulating the abundance and activity
of Bifidobacterium has demonstrated beneficial associations with health.
Keywords: microbiome; symbiosis; co-evolution; caesarean section; milk; host derived glycans;
human mik oligosaccharides; probiotics; prebiotics; synbiotics
1. Introduction
Intestinal microbiota development in early life is very dynamic and is in synergy with anatomical,
intestinal physiology, immune and neurological development [1]. Deviations and misconfigurations in
its structure and function may contribute to pathologies and chronic diseased states [2]. Timing of
the first microbial exposure to the developing embryo is often debated [3]: some reports suggest that
Microorganisms 2020, 8, 1855; doi:10.3390/microorganisms8121855 www.mdpi.com/journal/microorganisms
Microorganisms 2020, 8, 1855 2 of 20
microbial exposure and colonization already happens “in utero” [4–6] while others have pointed out
that more detailed studies are required to verify this observation [3].
Undoubtedly, there are many more parsimonious routes by which microbial inoculation may
proceed, including early exposure to vaginal and fecal microbiota at birth, ingestion of epidermal
skin microbes and viable microbes present in breast milk, as well as the inherently close interactions
between the neonate and mother [7]. The subsequent colonization process is a balance between influx
of microbes and niche adaptability [8].
These first microbial pioneers become key players in the assembly of a complex ecosystem that
follows distinct successional stages with potential long term health consequences [9]. The formation of
this complex ecosystem is influenced by multiple factors including host genetics, mother’s microbiota,
gestational age, medical practices, mode of delivery, diet, life style, familial environment, presence of
pets, infectious diseases and antimicrobial therapies [10]. Although microbiota assembly in the infant
gut is not strictly deterministic, there is an overarching directionality of microbial succession strongly
driven by early life nutrition, specifically human breast milk.
Human milk not only provides optimal nutrition for the infants but is also a reservoir of microbes
mainly within the genera Staphylococcus and Streptococcus but also Bifidobacterium, Propionibacteria,
Pseudomonas, Bacteroides and Parabacteroides [11,12]. Bifidobacterium is the most abundant genus in
the breastfed infant’s gut and is considered a true “keystone” taxon with a strong eco-physiological
impact on microbiota composition and activity. Therefore, Bifidobacterium spp. may serve as a marker
of healthy microbiota development and breast-feeding practices. The purpose of this review is to
highlight the central role of bifidobacteria as keystone organisms in early life, and compare their
distinct ecophysiology with other members of the early-life gut microbiota [8]. Furthermore, we aim to
provide mechanistic insights which support the application of bifidobacteria as microbiome modulators
(in conjunction with prebiotics) to restore compromised microbiota development linked to mode of
delivery, antibiotic exposure, prematurity and childhood pathology such as allergy.
2. Ecological Drivers of Acquisition and Succession of Bifidobacteria
2.1. Mode of Delivery, Antibiotics and Diet
Immediately after birth, the infant gut is still rich in oxygen and offers a favorable habitat for
facultative anaerobic microorganisms such as Staphylococcus spp., Streptococcus spp., Enterobacter spp.
and other members of family Enterobacteriaceae [10]. These pioneering species play an important
role in the rapid transition from a microbiome dominated by taxa that tolerate or thrive under
limited oxygen to microbiome dominated by strictly anaerobic taxa such as Clostridium, Bacteroides,
Eubacterium and Bifidobacterium spp. [2,10]. However, birth via caesarean section (c-section) interrupts
this program of microbiota acquisition and colonization since there is no contact with the maternal
vaginal and fecal microbiota and the perineal skin. In addition, c-section born infants are often exposed
to maternal prophylactic antibiotic administration and c-section birth has been shown to adversely
affect breastfeeding initiation, milk supply and infant breastfeeding receptivity compared to vaginal
deliveries, which may further compromise early life microbiota development. [13].
Instead, the guts of c-section-delivered infants are typically first colonized by human skin and
oral cavity associated bacteria, which include Staphylococcus spp., Streptococcus spp., Veillonella spp.,
Propionibacterium spp., Corynebacterium spp. and Acinetobacter spp. [7,14,15]. Recently, a large study with
596 infants confirmed microbiota differences observed in c-section born infants [16]. Notably, this study
reported that in vaginal born infants, commensal genera, such as Bacteroides and Bifidobacterium
(such as Bifidobacterium longum and Bifidobacterium breve and Bifidobacterium infantis), made up 68%
of the total genus richness, while c-section born infants were depleted of these commensal genera
and instead were enriched by species within the genera Enterococcus, Staphylococcus, Streptococcus,
Klebsiella, Enterobacter and Clostridium, all of which are more characteristic for hospital environments
and hospitalized preterm babies [16]. In addition, c-section delivery is often accompanied with varying
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use of medications, including prophylactic antibiotics, which further adds to the disrupted transfer of
maternal gut microbiota.
It has been shown that direct administration of antibiotics to neonates or indirect through
feto-placental circulation has pervasive effects on gut microbiota composition, and is associated with
adverse immune outcomes such as allergies and atopies [17], and metabolic health outcomes such as
obesity [18]. Fouhy et al. demonstrated that antibiotic administration to term neonates led to a relative
increase in fecal Proteobacteria and a decrease in Actinobacteria, particularly Bifidobacterium spp.,
representing deviation from normal microbiota development [19]. Intriguingly, it was also shown
that intrapartum antibiotic administration not only led to differences in infant gut microbiota but also
affected breast milk microbiota composition [20].
Upon delivery, breast milk is the most significant factor which impacts maturation of the gut
microbiota. It has been shown that formula-fed infants exhibit a more diverse microbiota than breastfed
infants [9,21,22]. The microbiota of vaginally delivered breast-fed infants is dominated by the Phylum
Actinobacteria, while formula-fed infants adopt a more diverse microbiota [23]. Moreover, the cessation
of breast feeding is associated with a steep reduction in the levels of bifidobacteria and an accelerated
increase in members of Firmicutes and Bacteroides, which further substantiates the key role of the
milk–bifidobacteria interaction in shaping the human gut microbiota [9].
2.2. Establishment of Bifidobacterium: A Keystone Genus
Bifidobacteria are regarded as a “keystone” taxon in the early life gut microbiota. The keystone
organism concept is a fundamental principle in theoretical and applied ecology. The term was first
introduced in a study on a rocky intertidal ecosystem in California. When the top predator (a starfish)
was removed, the community collapsed, prompting the architectural analogy with the keystone of an
arch [24]. Keystone organisms are important drivers of community structure and integrity, and their
influence is non-redundant. Their activity and biotic interactions disproportionately determine species
assemblages and the rates of material and energy flow across entire communities. These taxa have
a unique and crucial role in microbial communities, and their removal can cause a dramatic shift in
microbiome structure and functioning.
By their broad impact on microbiota composition function, keystone members are also likely to
exert strong direct and indirect effects on host physiology and may be essential for host homeostasis and
health [25]. In early life gut microbiota, Bifidobacterium and Bacteroides drive microbiota development
by maintaining a strict anaerobic environment, by producing and cross-feeding on metabolites such
as short chain fatty acids (SCFA). SCFA result in a low pH, which is among the main mechanisms
of ecological resistance against pathogens [26,27]. The failure of these keystone taxa to colonize and
drive succession may lead or contribute to the development of chronic diseases [28]. For instance,
antibiotics administration has been clearly demonstrated to impair proliferation of these keystone
taxa, which could in turn disturb microbial interaction with the immune system, particularly during
critical stages of development. This failure of cross talk between keystone microbes and immune cells
is thought to be an important factor in the development of allergies, metabolic disorders and infectious
diseases [29].
Physiologically, the keystone function of bifidobacteria is strongly linked to their unique
metabolic capacity and genomic architecture. Bifidobacteria are genetically adapted to utilize specific
glycans of human milk, thus representing an intriguing example of host-microbe coevolution into
mutualistic symbiosis.
3. Evolutionary and Eco-Physiological Attributes of a Bifidogenic Milieu
3.1. Evolutionary Ecology
The heterofermentative genus Bifidobacterium takes its name from its characteristic Y-shaped cells
(in Latin, bifidus means cleft or divided into two parts). Isolation of bifidobacteria from infant feces
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provided first indications of their ecological relevance in the human gut [30]. Interestingly, bifidobacteria
were also isolated from the gut of multicellular social organisms such as birds, mammals and social
insects, which implies that bifidobacteria could be transmitted vertically [31,32]. In the gut, growth of
bifidobacteria is nurtured by glycans through feeding or cross-feeding activity [33]. The unique
genetic make-up of Bifidobacterium species gives an advantage to outcompete other gut commensals in
metabolizing glycans present in human milk [30]. These two exceptional features—maternal transfer
and genetic constitution—distinguish bifidobacteria from all other commensal gut bacteria such as
Lactobacillus species.
Several studies investigating specific maternal–neonatal microbial transference have shown that
mother and child often share genomically identical bifidobacterial strains belonging to B. breve and
B. longum subsp. longum, B. longum subsp. Infantis, further substantiating vertical transmission of
bifidobacteria (Figure 1) [34–37]. These findings provide initial insights as to why vaginal delivery
provides a higher abundance of Bifidobacterium species in infants, over a c-section delivery.
Figure 1. Schematic overview of eco-physiological factors driving maternal transmission, colonization
and succession of Bifidobacterium species in the early life gut microbiota. (1) Seeding: Bifidobacteria
are transmitted from mother to child during vaginal delivery. (2) Nurture: Human milk contains
viable microorganisms, including Bifidobacterium species, which contribute to seeding the infant’s gut
microbiota. Human milk oligosaccharides (HMOs) are minimally digested by the infant and metabolized
by infant-type bifidobacteria by convergent mechanisms. (3) Feeding & Cross-feeding: different
Bifidobacterium species and strains have distinct HMO degrading abilities resulting in varied HMO
consumption behaviors. Degradation of HMO occurs sequentially with the removal monosaccharides
and requires a multitude of enzymes with various glycosidic specificities. Bifidobacterial cross-feeding
permits the sharing of resources to maximize nutrient consumption from the diet and highlights
the cooperative nature of bifidobacterial strains and their role as ”key stone” species in the infant
gut microbiota. (4) Succession: The combined activity of Bifidobacterium species contributes to the
establishment and maintenance of a strict anaerobic environment and low pH by producing metabolites
such as lactate and acetate. These conditions allow the successive establishment of butyrate producing
taxa such as Eubacterium and Anaerostipes spp which are characteristic for a more matured microbiota.
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In vaginally delivered breast-fed infants, the relative abundance of bifidobacteria could be over
90% but typically decreases to less than 5% in adults [38,39]. More specifically, breast-fed infants are
predominated by the presence of B. breve spp., B. bifidum, B. longum subsp. infantis and B. longum subsp.
longum, also known as infant type Human Resident Bifidobacteria (HRB) (Figure 1) [32]. On the other
hand, adults are characterized by the presence of B. adolescentis and B. catenulatum, B. pseudocatenulatum
and B. longum subsp. longum which are often termed as adult-type HRB [32,33]. Notably, B. longum
subsp. longum was found to be predominant in both infant and adult gut. Hence, there is no strict
distinction between “infant” type and “adult” type bifidobacteria, as some of the adult bifidobacteria
such as B. adolescentis were shown to be vertically transferred to infants [40].
3.2. Genomic Features
The typical characteristics of bifidobacteria include their obligate anaerobism, peptidoglycan rich
cell walls and heterofermentative metabolism. At present, there are 51 species and 10 subspecies
of bifidobacteria reported, out of which 48 (sub)species have at least one genome sequenced (NCBI
database) [41]. Pan-genome analyses of the Bifidobacterium genus revealed that 13.7% of the identified
bifidobacterial genes are involved in carbohydrate metabolism, which is much higher than the other
analyzed gut commensals [30,42]. Importantly, the core genome also encodes enzymes involved in the
“bifid shunt”, which equips bifidobacteria with a unique evolutionary advantage of generating more
ATP (per mole of glucose) in comparison to microorganisms using other carbohydrate fermentative
pathways such as glycolysis [30]. Specifically, a Cluster of Orthologous Groups (COGs) representing
α-amylases, ATP-binding cassettes (ABC) and phosphoenolpyruvate-phosphotransferase systems
(PEP-PTS) were identified to be acquired during the course of evolution and give bifidobacteria a
selective advantage in the highly competitive ecological niche of the early life gut [42]. Furthermore,
comparative genome analyses of bifidobacteria, particularly B. longum subsp. infantis ATCC15697 and
B. bifidum PRL2010, have revealed that these species are able to utilize a broad range of host-derived
glycans (HMOs and mucin), further corroborating the genomic plasticity of Bifidobacterium spp. [30].
3.3. HMO Utilization
Human milk constitutes around 10–12 gm/L of oligosaccharides, which constitute the third most
abundant component in milk [43,44] (Figure 1). HMOs are complex and structurally highly diverse,
with over 200 different molecules that vary in size, Degree of Polymerization (DP), charge and sequence.
The size distribution of HMOs ranges from 90% short chain oligosaccharides to 10% long chain
oligosaccharides [45]. The most basic HMO structures are monomers of glucose (Glc), galactose (Gal)
and N-acetylglucosamine (GlcNAc), and also contain fucose (Fuc) and/or N-acetylneuraminic acid
(NeuAc) linked via several glycosidic bonds [46]. Most HMOs cannot be utilized by host digestive
enzymes but are effectively utilized by gut microbiota. Therefore, HMOs play a pivotal role in shaping
the infant gut microbiota, and actively promote beneficial bacteria, which is also termed as a “prebiotic”
effect [47].
The abundance and prevalence of Bifidobacteria in the neonatal gut is attributed to their unique
ability to catabolize HMOs [48]. For example, B. longum subsp. infantis and B. breve use specific
ATP-binding cassette (ABC) transporters for internalization of intact oligosaccharides. Intracellular
glycosyl hydrolases (GH) such as fucosidases, hexosaminidases and sialidases can further deconstruct
the oligosaccharides [49,50] (Figure 1). Species such as B. bifidum have different HMO consumption
capabilities. These taxa break down HMO via extracellular glycosidases into mono- and disaccharides,
which are subsequently transported into the cells via permeases. Residues of this extracellular
degradation allow cross-feeding of other types of bacteria including other Bifidobacterium species [51].
Preclinical experiments in conventional mice receiving a combination B. bifidum PRL2010, B. longum
subsp. infantis ATCC15697, B. adolescentis 22L, and B. breve 12L, demonstrated a synergistic effect by
acting directly or by cross-feeding on host or plant derived carbohydrates, which further led to the
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enrichment of murine gut glycobiome [52]. In contrast, other gut commensals such as Lactobacillus sp.
and Bacteroides sp. show poor or limited capacity to utilize HMOs, respectively [50,53].
Short chain galacto-oligosaccharides (scGOS) and long chain fructo-oligosaccharides (lcFOS) in
a ratio of 9:1 mimic the size distribution of HMOs and resembles functionality of breast milk [54].
Based on these observations, scGOS/lcFOS, and synthetic HMOs such as 2′Fucosyl Lactose (2′FL) and
Lacto-N-neotetraose (LNnT), are being incorporated in infant formula. Altogether, these chemical
constituents or prebiotics are aimed to increase bifidobacteria counts and thereby exert immune benefits.
In clinical studies, it was demonstrated that 2′FL and LNnT modulated the gut microbiota exhibiting
increased levels of Actinobacteria, specifically Bifidobacterium spp., and decreased levels of Firmicutes
and Proteobacteria [55,56].
3.4. Effect on pH and SCFA Production
In breast-fed infants, HMO metabolism by gut microbiota is often associated with distinct SCFA
profiles when compared to formula-fed infants, which are subsequently reflected in reduced fecal
pH [57,58]. The prevalent SCFAs include acetate, butyrate, valerate, propionate and, to a lesser extent,
branched chain fatty acids such as iso-butyrate and iso-valerate. Exclusively breast-fed infants are
characterized by a higher relative proportion of acetate relative to other SCFAs in the gut, which was
found to be independent of birth mode, sex, intrapartum antibiotics, site of recruitment and maternal
body mass index [57–59]. Importantly, Bifidobacteriaceae was the only family which was significantly
associated with fecal pH, although there are microbes (such as Bacteroidaceae) which can also utilize
HMO [27,60]. In particular, bifidobacteria have evolved with specific mechanisms to produce acetic
and lactic acids (in a molar ratio of 3:2) by utilization of glycans through the bifid shunt pathway
(Figure 1). [61]. Based on these observations, fecal acetate is also regarded as a biomarker for bifidogenic
activity and overall microbiota health in early life.
Physiologically, SCFAs have also been associated with both systemic effects such as immune
modulation and local effects such as acting as an energy source for colonocytes. SCFAs may also provide
colonization resistance against pathogens such as Escherichia coli O157:H7 [57,62]. In a clinical study,
reduced fecal acetate at 3 months of age was associated with atopic wheeze observed 9 months later [63].
In addition, it was recently shown that prebiotic supplementation (short chain galacto-oligosaccharides
(scGOS) and long-chain fructo-oligosaccharides (lcFOS)) in a partially hydrolyzed protein formula, led
to increased Bifidobacterium/Lachnospiraceae ratio, which in turn was reflected in organic acid profiles
with high acetate and lactate levels and low butyrate, propionate and branched chain SCFAs [64].
On the other hand, butyrate is considered as a marker for a healthy maturation of the gut
microbiota when the infant diet diversifies with the introduction of solid foods [58,65]. Interestingly,
acetate and lactate are important “cross-feeding” substrates for butyrate-producing bacteria such
as Faecalibacterium prausnitzii, Roseburia, Anaerostipes spp. and Eubacterium halli (Figure 1) [66].
This gradual transition from a bifidogenic and acetogenic milieu towards a butyrogenic milieu (more
adult like) may be of critical importance for a healthy maturation of the gut and the gut microbiota.
Wopereis et al. (2017) proposed that this maturation process is associated with a reduced risk of
developing eczema in infants at risk of developing allergies [64]. Moreover, butyrate has been shown
to have regulatory effects on host immunity including anti-inflammatory mechanisms and has been
generally associated with numerous health benefits by improvement of gut barrier function and
pathogen inhibition [67].
4. Infant Type Bifidobacteria as Indigenous Probiotics
Probiotics are live beneficial microorganisms which, when administered in adequate amounts,
confer health benefits [68,69]. The conferred health benefits are mostly attributed to immunomodulation,
restriction of pathogenic bacteria through competitive exclusion, SCFA production and modulation of
mucosal barrier function [70]. Among early life microbial colonizers, members of genera Streptococcus,
Enterococcus, Bacillus, Escherichia, Propionibacterium and Lactococcus and also yeasts such as Saccharomyces
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species, have been widely used as probiotics for a broad range of health benefits. Notably, bifidobacteria
and lactobacilli are two of the most exploited taxonomic groups for probiotic applications [68,69].
Nonetheless, there have been documented efforts to characterize combinations of other commensal
microorganisms directly isolated from healthy infants, for maintaining or even restoring normal gut
microbiome composition to benefit host health [71].
Historically, the selection of probiotic strains for human applications is often based on technological
criteria rather than ecological or clinical criteria [72]. In order to survive gastric passage and efficiently
colonize and proliferate in the human gut, a probiotic strain needs to be tolerant to low pH, bile salts
and proteolytic enzymes [68,69]. For some probiotics, adhesion to the intestinal mucosa is essential
for colonization [73]. On the other hand, technological application requires resistance to processing
conditions (including exposure to oxygen) and viability and stability in products over longer periods.
Maintaining viability in products over a period of time (i.e., shelf-life) is often a major selection criterion
for the choice of probiotics for commercial exploitation. Consequently, on technological grounds,
Lactobacillus spp. are historically much more exploited for probiotic applications than other taxa such
as Bifidobacterium spp. However, Lactobacillus spp., are sometimes found to be less adaptive to host
conditions and may not sustain in the highly competitive ecological niche of the early life gut [74]. On the
other hand, physiological properties of probiotics such as folate production, carbohydrate metabolic
affinities and tolerance to stress are host dependent [32]. Therefore, eco-physiological adaptability
and clinically relevant host–microbe interactions should be clearly very important parameters for the
selection and development of probiotics.
Given the abundance in the early life gut, their HMO-driven symbiotic relationship with
humans and the beneficial associations with health, bifidobacteria are often considered as ideal
probiotics for infants. Delayed bifidobacterial colonization has been reported in cases of compromised
delivery such as c-section and pre-term birth, or in the case of early life antibiotic exposure
(Figure 2) [75]. Interestingly, bifidobacterial transmission is influenced by maternal factors before
delivery. Nuriel-Ohayon et al. (2019) reported that there is a dramatic change in gut microbiota during
pregnancy and bifidobacteria are enriched in late pregnancy—i.e., third trimester [76]. The authors also
postulated that a rise in the level of Bifidobacterium is not only beneficial for healthy pregnancy but also
reveals an evolutionary process that facilitates optimal transmission during birth and lactation [76,77].
In an independent study, it has been shown that women with excessive weight gain during pregnancy
harbored lower numbers of Bifidobacterium spp. and Bacteroides spp. in their gut compared to pregnant
women who had normal weight gain [78]. Therefore, bifidobacterial probiotics hold great potential for
the restoration of compromised microbiota development, particularly in early life and are already used
in currently commercialized probiotic infant nutrition products
4.1. Comparison with Probiotic Lactobacillus Species
Lactobacillus spp. have been extensively studied for probiotic applications and their general impact
on host health. However, from an ecological perspective, only a small number of Lactobacillus spp.
can be considered truly indigenous inhabitants of the human intestinal tract. Most industrialized
Lactobacillus spp. have originally been isolated from fermented foods, the human oral cavity or
sometimes proximal parts of the gastrointestinal tract [74]. Various studies have shown that
the distribution of other dominant gut microbiota taxa, such as Bifidobacterium, Bacteroides and
Clostridia, exhibit higher temporal stability compared to Lactobacillus spp. [74]. Especially in early life,
Lactobacillus spp. are less abundant than Bifidobacterium spp. and their presence is mostly transient and
driven by “chance colonization” processes immediately after birth [72]. Lactobacilli are members of the
Phylum Firmicutes which are taxonomically and genetically distinct from the Phylum Actinobacteria
to which the genus Bifidobacterium belongs.
In particular, infant-type Bifidobacterium spp. have evolved with a genetic makeup which is
adapted for metabolizing host derived glycans, while Lactobacillus spp. typically have a more diverse
carbohydrate metabolizing capacity [79]. Based on their evolutionary ecology and carbohydrate
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fermentation capacity, members of the genus Bifidobacterium are more likely to be stable colonizers of
the infant gut [79] which is a desirable attribute for probiotic applications. Probiotic attributes of infant
type Bifidobacterium spp. and subspp. such as B. bifidum, B. longum subsp. longum, B. longum subsp.
infantis and their species specific relevance in infant health have been extensively reviewed [80–83].
In the following section, we summarize scientific evidence available for B. breve-based probiotic
solutions in early life development and specific clinical conditions.
4.2. Beneficial Effects of Bifidobacterium Breve Strains on Infant Health
The history of dairy products supplemented with Bifidobacterium dates back to the early 1970s,
and products have been marketed since the early 1980s in Japan [84]. Moreover, due to their
eco-physiological function and perceived health benefits, Bifidobacterium spp. have been widely
used as probiotic supplements for infants and young children. Specifically, probiotic applications
of Bifidobacterium breve strains such as BBG-001, BR-03, B632, M-16V, BB536, CNCM I-4035 and C-50,
have been documented [85].
B. breve strains have demonstrated antipathogenic, anti-inflammatory and immune-modulating
properties [86]. Immune benefits of B. breve strains have been reported in infants with allergic disorders,
in very low birth weight infants and in prevention of late-onset sepsis and necrotizing enterocolitis
in preterm infants [87,88]. Apart from immune mediated health benefits, positive effects of B. breve
strains have also been observed in children with antibiotic associated diarrhea [89], in pediatric patients
undergoing chemotherapy [90] and in children with celiac disease [91].
B. breve strains combined with digestible substrates—i.e., prebiotics—may further the synergistic
health effects on the host (Figure 2). The combination of scGOS/lcFOS and B. breve M-16V supplemented
with an extensively hydrolyzed formula demonstrated to be well tolerated in healthy term infants,
and supported an adequate infant growth [92]. In infants with suspected non-IgE mediated
cow’s milk allergy, an amino-acid-based formula (AAF) supplemented with a synbiotic blend of
fructo-oligosaccharides and B. breve M-16V was shown to improve the gut microbiota composition by
modulating bifidobacterial levels and Eubacterium rectale/Blautia coccoides taxon levels closer to that of
healthy breast fed infants [93].
B. breve strains also produce metabolites which can have a direct or indirect impact on the host health.
For example, in a preclinical model, it was demonstrated that cell surface associated exopolysaccharide
(EPS) of B. breve UCC2003 reduced the colonization of the gut pathogen Citrobacter rodentium [94].
Bacterial metabolites or bioactive compounds produced during the fermentation process—i.e.,
postbiotics—could also exert a beneficial effect on the host [95,96].
Postbiotics may include metabolites such as SCFA, saccharides such as polysaccharide A,
secreted molecules such as lactocepin and p40 molecules [96]. Infant formula with postbiotics
originating from fermentation by S. thermophilus (ST065) and B. breve C50 (BbC50) strains have
been shown to enhance the production of intestinal sIgA [97] and resulted in less severe diarrheal
episodes [98].
Another evolving strategy of gut microbiota modulation could include a combination of prebiotics
and postbiotics. For instance, a clinical study with a partially fermented (postbiotic) formula
supplemented with scGOS/lcFOS in a ratio of 9:1 resulted in reduced incidence of infantile colic and
increased sIgA in addition to more bifidobacteria and less pathogenic bacteria such as clostridia-related
species [99,100]. Taken together, these examples of microbiota modulation strategies based on
probiotics/prebiotics/postbiotics or combinations thereof, are closely associated with the unique
metabolic characteristics of B. breve strains.
4.3. Preterm Infants
Preterm birth (PTB), defined as birth at fewer than 37 weeks gestational age, is a major cause
of neonatal morbidity and mortality. Globally, 14.8 million babies are born prematurely. In both
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developed and underdeveloped countries, PTB rates have not significantly decreased in the past
40 years and in some cases have increased [101].
Some of the common complications of preterm birth include high rate of respiratory distress
syndrome, Necrotizing Enterocolitis (NEC), early- and late-onset sepsis, cerebral palsy, infections and
feeding difficulties [101]. These health complications are mainly associated with immature organ
systems that are not yet prepared to support life in the extrauterine environment. As a consequence
of preterm delivery, the development of gut microbiota is also impacted and preterm infants
have taxonomically less diverse microbiota with increased abundance of facultative anaerobes
(Figure 2) [102–104]. These differences in microbiota composition could be attributed to the intensive
care environment and extensive use of antibiotics after birth. This is supported by the observation that
interindividual differences in microbiota composition of hospitalized very low birth weight infants
becomes smaller with increasing stay [105,106]. More specifically, the microbiota of hospitalized infants
converges toward a microbiota enriched with bacterial families Enterobacteriaceae and Enterococcaceae,
including members of the genera Klebsiella, Enterobacter and Clostridium and depleted of beneficial
genera such as Lactobacillus and Bifidobacterium [14,107].
Compromised microbiota composition in combination with under-developed immune system
may leave preterm infants susceptible to contracting nosocomial infections, such as NEC and sepsis.
Prophylactic treatment with broad-spectrum antibiotics, such as amoxicillin, ceftazidime, erythromycin
and vancomycin, is common practice in neonatal wards for the prevention and treatment of infections
and sepsis.
Figure 2. Impact of microbiome (including Bifidobacterium spp.) modulation strategies on early life and
later life health outcomes. Advertent early life events such as pre-term birth or antibiotic exposure
may already initiate a derailed microbial succession, which may be further amplified by poor diet and
life-style, repeated antibiotic exposure, medications or disease. All these factors have been reported to
contribute to the later life health outcomes such as allergy or non-communicable diseases. Restoration
of the compromised microbiota involves accelerating the process of succession or attempting to change
the trajectory of succession by microbiome modulation strategies.
While antibiotics decrease mortality and morbidity rates on the one hand, they also pervasively
disrupt early-life microbiota development and specifically delay Bifidobacterium colonization [108].
To mitigate the health risks associated with compromised microbiota development, probiotic
supplementation is now increasingly recognized as routine therapy for preterm infants. B. breve
M-16V is among the widely used probiotics in preterm infants and has been shown to significantly
reduce the incidence of NEC [86,109]. Furthermore, supplementation with B. breve M-16V to extremely
preterm infants was found to be effective in restoring the normal gut microbiota composition [109].
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Furthermore, a systematic review of the applications of B. breve M-16V in preterm neonates concluded
that B. breve M-16V is safe and showed no adverse effects. However, a multicenter clinical study that
included 1300 preterm infants did not conclusively demonstrate a clinical benefit of supplementation
with B. breve-001 [110], which corroborates that probiotic effects can be highly strain specific. Based
on these mixed observations, adequately powered Randomized Clinical Trials (RCTs) are needed to
confirm the findings and to support the routine use of bifidobacterial probiotics in preterm infants [111].
4.4. Cesarean Section
Globally, birth through c-section has almost doubled from year 2000 (12.1%) to year 2015
(21.1%) [112]. This extra-ordinary rise in c-section delivery may have health consequences. In particular,
C-section is associated with an increased risk of immune diseases, such as asthma, eczema and
allergies [113]. Although the mechanistic links between c-section and immune function are not fully
established [114,115], there are ample reports that demonstrate the role of birth mode on early life
microbiome colonization. It has been suggested that observed C-section effects on gut microbial
colonization are associated with resulting unintended intrapartum exposure to broad-spectrum
antibiotics in all C-section born neonates (Figure 2) [116]. However, Reyman et al. (2019) demonstrated
by postponing antibiotic administration to mothers until after cord clamping that the effect of C-section
birth on gut microbiota is largely independent of intrapartum antibiotics [117,118].
To restore microbiota development in c-section-delivered infants, there are multiple strategies
which are being explored. One such strategy is vaginal seeding: inoculating a gauze or swab with
vaginal fluids to transfer the vaginal flora to the mouth, nose or skin of a newborn infant. Evidence
from a small pilot study indicated that vaginal seeding partially restores the microbiome of c-section
delivered neonates [119], but larger, more rigorous studies are needed to assess the effect of vaginal
seeding on microbiome trajectories and health outcomes. Of additional concern is that 20% of pregnant
women at term are carriers of group B streptococci. Furthermore, undiagnosed carriage of C trachomatis,
N gonorrhea, human papilloma virus and herpes simplex virus infections, among others, could result in
adverse exposure to these pathogens. [120].
A more controlled strategy could be to use probiotics or prebiotics: for instance, Lactobacillus rhamnosus
GG supplementation during pregnancy was found to be effective in modulating the gut microbiota
and also resulted in enrichment bifidobacteria in neonates [121].
Barret et al. (2015) showed that prebiotic (GOS and poly-fructose) supplementation during
the first four weeks of life led to increased prevalence of Bifidobacterium longum and also promoted
bifidobacteria strain diversity [122].
A more recent clinical study by Chua et al. (2017) demonstrated that specific synbiotics—short
chain galactooligosaccharides and long chain fructooligosaccharides (scGOS/lcFOS) in combination
with B. breve M-16V—compensates the delayed Bifidobacterium colonization in C-section-delivered
infants and modulates the production of acetate and the acidification of the gut. [123]. All these
nutritional approaches are targeted to restore the complete microbiota composition and the gut milieu
in c-section delivered neonates, which further substantiates the key role of vertical transfer and
maintenance of Bifidobacterium spp. in neonates (Figure 2).
5. Allergy Development
In the last 50 years, the global prevalence of allergic diseases has consistently increased and is
expected to reach up to 4 billion people by 2050 [124]. Although there is a strong genetic link attributed
to the perceived allergy epidemic, it rarely starts at birth.
According to recent reports, early exposure to specific microbial taxa is quintessential for immune
training. Suboptimal transfer of microbes such as in the case of infants born by c-section, exposed
to antibiotics or formula feeding are risk factors attributed to allergy development (Figure 2). In a
landmark study by Kalliomaki et al., it was shown that atopic infants at 3 weeks of age had significantly
higher clostridia to bifidobacteria ratios [125]. This observation was further substantiated by another
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study conducted in Turkey, which showed that B. longum was present in significantly lower amounts in
allergic children (age: 0–3 years) than in healthy controls [126]. A high level of adult-type bifidobacteria
such as B. pseudocatenulatum and B. catenulatum and low level of infant type bifidobacteria such as
B. breve were also found to be associated with eczema development [126–128]. These findings further
support the relevance of bifidobacterial colonization in early life and suggest that inadequate transfer
of bifidobacteria might precede allergy development.
In children with atopic dermatitis (AD), it was demonstrated that the synbiotic supplementation
(B. breve M-16V and scGOS/lcFOS) could prevent asthma-like symptoms, while in asthmatic adults,
this synbiotic mix reduced allergen-induced immune responses [87,129]. Furthermore, in infants with
AD, the combination of B. breve M-16V with scGOS/lcFOS did not show any effect on AD, while in a
subgroup of infants with IgE associated AD, resulted in a significant reduction in AD [130]. In the
case of infants with a cow’s milk allergy, amino acid formula when supplemented with B. breve
M-16V and scFOS/lcFOS modulated the microbiome composition closer to the healthy breast-fed
infants [93]. These findings support the hypothesis that inadequate microbiome colonization is
key in the manifestation of allergic diseases and that Bifidobacterial levels in early life align with
key stages in immune maturation. Studies have shown that bifidobacteria mediate a dialogue
with mucosa-associated immune cells, having both pro- and anti-inflammatory effects promoting
antipathogen immune responses [86,131].
Several studies show immune receptor–ligand interactions and immune signaling pathways linked
to specific bifidobacterial compounds, such as pili and exopolysaccharide (EPS) [94,131–133]. Although,
in most cases, the molecular mechanisms involved are not fully understood, these observations
hold great promise for translation into microbiota modulation strategies for allergy prevention
and management.
6. Emerging Relevance of Bifidobacteria in Later Life
Although bifidobacterial predominance is most pronounced in infants, especially during lactation,
it is still among the most abundant genera in adults [40]. Among all the bifidobacterial species,
B. adolescentis is the most frequently isolated species in adults [134–136]. Genotypic and phenotypic
characterization of B. adolescentis strains have revealed their extensive metabolic capabilities in utilizing
diet derived glycans, such as starch, poly- and oligo-saccharides, amylopectin, pullulan, maltotriose
and maltodextrin [137]. However, B. adolescentis lacks genes involved in metabolism of host-derived
glycans such as mucin and human milk oligosaccharides, which differentiates it from other infant
type bifidobacteria.
In elderly people, there is a gradual decline in bifidobacterial abundance which is accompanied
by decreased microbial diversity [40]. This has been repetitively confirmed by several studies using
different technologies [138–141]. In a recent Japanese cross-sectional study, changes in Bifidobacterium
abundance was investigated during the entire life span (age 0 – 104 years) (n = 441) [39]. The B. longum
group was the most prevalent taxon across the life span, while B. breve was detected in almost
70% of children under the age of 3. In adults, total abundances of bifidobacterial species were low,
but B. adolescentis and B. longum subsp. longum were found to be often prevalent in centenarians.
B. adolescentis and B. longum subsp. longum have been hypothesized to benefit centenarians by enhancing
immunity [39,142,143].
In old age, there is reduced immune tolerance, reduced immune memory and immune surveillance,
and these immunological changes are associated with increased risk of infection and illnesses such as
cystic fibrosis, hepatitis B and both diabetes Type 1 and 2 [40,144]. Specific probiotic strains are known
for their immunomodulating properties; therefore, the application of probiotics is also gaining interest
for applications in ageing populations. For instance, consumption of probiotic Bifidobacterium lactis Bi-07
in healthy elderly adults has been shown to enhance phagocytic activity of monocytes and granulocytes
and thereby increased immune tolerance [145]. Elderly people commonly experience higher incidence
of gastrointestinal symptoms such as constipation. A clinical study by Pitkala et al. (2007) demonstrated
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that probiotic administration in a fermented oat product—i.e., B. longum and B. lactis—led to an increase
in the frequency of bowel movements in Finnish elderly subjects [146]. Taking into account all of these
recent clinical observations, there is a clear potential for using bifidobacteria-based probiotics in adults,
more specifically in the ageing population.
7. Conclusions
Rapid changes in human lifestyles over the past 100 years, including profound changes in
modern-day infant nutrition and birthing practices [147], have had a profound impact on early life
microbiota acquisition [148] and may specifically impact the colonization by bifidobacteria. Immediately
after birth, the physicochemical properties and the continued availability of HMOs offer a strong
selective advantage for early-life type Bifidobacterium spp. Comparisons of infants with varying
Bifidobacterium abundances in early life are necessary to understand how the loss of this keystone taxon
and its critical ecological function impacts overall infant health and development.
Childbirth by c-section, premature birth and decreased limit of gestational viability, and exposure
to intrapartum antibiotics during delivery, have become increasingly common in both developed and
developing countries and have been very effective in saving maternal and infant lives. However,
these deviations from the natural process of delivery also impact microbiome acquisition in infants
and are increasingly being recognized as potential risk factors for diseases such as allergy. Increasing
the bifidobacterial abundance by means of probiotics, prebiotics or postbiotics is among the evolving
strategies to re-introduce bifidobacteria as a keystone species and hence impact health in early life.
The Bifidobacterium sp. “types”, which are broadly categorized into two classes—infant type (i.e.,
dominant in early life) and adult type (i.e., dominant in adults)—further emphasize the importance
of age appropriate probiotics. There is ample clinical evidence which supports the application
of B. breve strains in children with allergy, born by c-section or born prematurely. More recently,
bifidobacteria-based probiotics and synbiotics are also being investigated in adults and aging subjects
and hence could contribute to overall health. Although probiotic applications are always strain specific,
adequately designed clinical trials in larger cohorts of interest are still warranted.
Microbiota transmission from mother to child is a controlled process. It has been demonstrated that
the keystone microbes that drive early life gut microbiota development are acquired mostly vertically
under ecological selection mechanisms, rather than through chance-driven processes. Nevertheless,
a better understanding of the potential internal and external drivers of strain inheritance and selection
by infants in early life is still needed.
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